EUPRAXIA PHARMACEUTICALS INC.
For the period ended Dec 31, 2024. Filed Mar 20, 2025.
View on SEC.govAbout this filing
The yearly report of certain Canadian companies, filed under a joint US and Canadian system. It is the main yearly account these companies give US investors, largely as filed in Canada.
FY2024 · Filed Mar 20, 2025
Use the contents to explore the available documents and sections.
EPRX$6.89+4.4%Stored close · as of Nov 6, 2026
Contents
EX-99.1 · ANNUAL INFORMATION FORM
ANNUAL INFORMATION FORM
Dated March 20, 2025
TABLE OF CONTENTS
| INTRODUCTION | 1 |
|---|---|
| CAUTION REGARDING FORWARD-LOOKING STATEMENTS AND RISK FACTORS | 1 |
| CORPORATE STRUCTURE | 8 |
| General | 8 |
| Intercorporate Relationships | 8 |
| GENERAL DEVELOPMENT OF THE BUSINESS | 9 |
| Three-Year History | 9 |
| DESCRIPTION OF THE BUSINESS | 13 |
| RISK FACTORS | 39 |
| Risks Relating to Our Limited Operating History, Financial Position and Capital Requirements | 39 |
| Risks Relating to the Company’s Business | 39 |
| Risks Relating to Marketing, Reimbursement, Healthcare Regulations and Ongoing Regulatory Compliance | 89 |
| Risks Relating to our Securities | 94 |
| DIVIDENDS | 100 |
| CAPITAL STRUCTURE | 100 |
| Common Shares | 102 |
| Preferred Shares | 102 |
| MARKET FOR SECURITIES | 102 |
| Trading Price and Volume | 102 |
| Prior Sales | 104 |
| DIRECTORS AND OFFICERS | 104 |
| Cease Trade Orders, Bankruptcies, Penalties and Sanctions | 106 |
| Conflicts of Interest | 107 |
| PROMOTERS | 107 |
| AUDIT COMMITTEE INFORMATION | 107 |
| LEGAL PROCEEDINGS AND REGULATORY ACTIONS | 109 |
| INTEREST OF MANAGEMENT AND OTHERS IN MATERIAL TRANSACTIONS | 110 |
| TRANSFER AGENT AND REGISTRAR | 110 |
| MATERIAL CONTRACTS | 110 |
| INTERESTS OF EXPERTS | 110 |
| ADDITIONAL INFORMATION | 110 |
| SCHEDULE “A” Audit Committee Charter | 111 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.